Eli Lilly is undertaking a strategic transformation that will result in the formation of new business units. The Indianapolis company’s Bio-Medicines unit will split into two separate businesses, with one focused on neuroscience and the other concentrated on immunology.

Activist investor Elliott Management continues to push for a change in leadership at GlaxoSmithKline ahead of the planned 2022 split of the company.

GlaxoSmithKline Chairman Sir Philip Hampton will step down from his role ahead of the company’s plan to split into two separate business units.

Pfizer, which was considering a split into two companies for more than two years, said it would not do so because the move would not create any shareholder value.

Medivir AB announced that it plans to split up into two independent companies.